Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05712577
Other study ID # MarfanPsy
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 9, 2023
Est. completion date October 9, 2024

Study information

Verified date January 2024
Source IRCCS Policlinico S. Donato
Contact Alessandro Pini, MD
Phone +390252774705
Email alessandro.pini@grupposandonato.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to identify key factors leading to psychotherapy or psychological support in adult subjects with Marfan syndrome (MSF). the main questions it aims to answer are: - Understand and define which internal variables of the individual drive this request for psychological support; - To learn about verify the impact that the clinical manifestations of MSF have on psychosocial aspects, self-esteem, subjective perception of the disease and coping mechanisms.


Description:

Patients following psychological interview during follow-up visits will be enrolled in the study. The following self-report questionnaires will be used in understanding the impact the syndrome has on mental health and quality of life: - Rosenberg Self- Esteem: 10 item Likert scale for assessing self-esteem; - SF 36: 36 item scale assessing eight domains: physical functioning physical role limitations; bodily pain; general health perceptions; energy/vitality; social functioning; emotional role limitations and mental health; - Cope NVI: to test measures coping behaviors as potential responses to stressors like social support, avoidance strategies, positive attitude, problem orientation and transcendent orientation; - OQ45.2: measure of general psychological distress.


Recruitment information / eligibility

Status Recruiting
Enrollment 125
Est. completion date October 9, 2024
Est. primary completion date October 9, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects affected by Marfan syndrome; - Subjects currently in follow-up at Cardiovascular Genetic Centre, IRCCS Policlinico San Donato; - Signed informed consent. Exclusion Criteria: - Subjects with cognitive deficits

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Questionnaire
Rosenberg Self- Esteem scale
Questionnaire
Short Form 36 scale
Questionnaire
Coping orientation to the problems experienced - New Version in Italian
Questionnaire
Outcome Questionnaire - version 42.5

Locations

Country Name City State
Italy IRCCS Policlinico San Donato San Donato Milanese Lombardia

Sponsors (1)

Lead Sponsor Collaborator
IRCCS Policlinico S. Donato

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Questionnaire performance Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables.
Questionnaire scoring:
- COPE NVI: scoring between 60 and 240; higher score means better outcome
8 Months
Primary Questionnaire performance Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables.
Questionnaire scoring:
- Short Form-36: scoring between 0 and 100; higher score means better outcome
8 Months
Primary Questionnaire performance Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables.
Questionnaire scoring:
- Rosenberg Self- Esteem scale: scoring between 0 and 30; higher score means better outcome
8 Months
Primary Questionnaire performance Statistical analysis between the two experimental groups using independent samples t-tests for continuous variables and associations for categorical variables.
Questionnaire scoring:
- Outcome questionnaire 42.5: socring between 0 and 180; clinical cut-off value is 64, higher score means worse outcome
8 Months
See also
  Status Clinical Trial Phase
Recruiting NCT05794217 - A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
Completed NCT03680365 - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Completed NCT03290469 - NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants N/A
Not yet recruiting NCT05955794 - Vocal Pattern Assessment as a New Key to Identifying Rare Syndromes N/A
Recruiting NCT04429750 - Intact Cord Resuscitation in CDH N/A
Not yet recruiting NCT04152876 - Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power
Recruiting NCT03683966 - MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
Not yet recruiting NCT04319796 - European Registry on Rare Neurological Diseases
Completed NCT02736565 - Pbi-shRNAâ„¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma Phase 1
Completed NCT05070988 - Oral Health Related Quality of Life of Patients With Rare Diseases: a Qualitative Approach
Completed NCT03563677 - Dual Guidance Structure for Evaluation of Patients With Unclear Diagnosis in Centers for Rare Diseases N/A
Recruiting NCT05499091 - Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN N/A
Completed NCT03954652 - Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH" N/A
Recruiting NCT05703893 - Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
Enrolling by invitation NCT04703179 - Rare and Undiagnosed Disease Research Biorepository
Recruiting NCT04024774 - Diagnostic Research in Patients With Rare Diseases -Solving the Unsolved Rare Diseases
Recruiting NCT06343558 - Gait and Balance Impairment in Rare and Very Rare Neurological Diseases
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Enrolling by invitation NCT04654000 - Rheopheresis as Adjuvant Treatment of Calciphylaxis N/A
Recruiting NCT04651439 - Severe Bullous Drug Eruption and Filgrastim Phase 2/Phase 3